期刊文献+

复方斑蝥胶囊联合 CHOP 化疗治疗恶性淋巴瘤疗效观察 被引量:3

Observation on Clinical Efficacy of Compound Cantharidin Capsule Combined with CHOP Chemo-therapy for the Treatment of Malignant Lymphoma
下载PDF
导出
摘要 【目的】探讨复方斑蝥胶囊联合CHOP方案化疗对恶性淋巴瘤患者的临床近期疗效。【方法】本院收治的97例恶性淋巴瘤患者,分为对照组( n=51)及观察组( n =46)。对照组单用CHOP方案化疗,观察组在CHOP方案基础上加用复方斑蝥胶囊(一次3粒,每天2次口服)。21 d后重复化疗;疗程结束后进行疗效评定。【结果】观察组总有效率为78.26%(36/46);对照组总有效率为64.70%(33/51);观察组总有效率显著高于对照组,且两组相比较差异有显著性( P <0.05);K PS评分改善率分别是86.96%和66.67%%,且两组相比较差异有显著性( P <0.05);观察组中不良反应低于对照组,且两组相比较差异有显著性( P <0.05)。【结论】复方斑蝥胶囊联合CHOP化疗治疗恶性淋巴瘤的临床近期疗效显著,不良反应低,值得临床推广应用。 [Objective]To explore the short‐term efficacy of compound cantharidin capsule combined with CHOP chemotherapy for the treatment of patients with malignant lymphoma .[Methods]Totally 97 patients with malignant lymphoma in our hospital were divided into control group( n=51) and observation group( n=46) .The control group received CHOP regimen ,while the observation group received CHOP regimen combined with oral compound cantharidin capsule(3 capsules once ,twice daily) .Chemotherapy was repeated after 21 days .The effi‐cacy was evaluated after treatment .[Results]The total effective rate in observation group was 78 .26% (36/46) which was markedly higher than that in control group(64 .70% ,33/51) ,and there was significant difference( P〈0 .05) .The improvement rate of KPS in observation group and control group was 86 .96% and 66 .67% respective‐ly ,and there was significant difference( P 〈0 .05) .The incidence of adverse reaction in observation group was lower than that in control group ,and there was significant difference( P〈0 .05) .[Conclusion]Compound canthar‐idin capsule combined with chemotherapy for the treatment of malignant lymphoma has significant short‐term effi‐cacy .Therefore ,it is worthy of clinical promotion .
作者 杨常成 何丹
出处 《医学临床研究》 CAS 2014年第10期1944-1945,1948,共3页 Journal of Clinical Research
关键词 斑蝥/治疗应用 抗肿瘤药(中药)/治疗应用 淋巴瘤/药物疗法 MYLABRIS/TU ANTINEOPLASTIC DRUGS (TCD)/TU Lymphoma/DT
  • 相关文献

参考文献8

二级参考文献97

共引文献113

同被引文献25

  • 1谢哲,黄达仁.CHOP方案治疗恶性淋巴瘤32例临床分析[J].海南医学,2005,16(5):28-29. 被引量:2
  • 2郑晓萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002.60-66.
  • 3蒋茜,张慧,焦志军,等.HBV感染与恶性淋巴瘤的关系[C].中华医学会第七次全国中青年检验医学学术会议论文集.2012:226-227.
  • 4Cheson BD, Pfistner B,Juweid ME, et al .Revised responsecriteria for malignant Iymphoma[J]. J Clin Oncol? 2007,25(5):579-586.
  • 5中华医学会肝病学分会,中华医学会消化病学分会.肝脏生化试验的分析与监测共识意见(草案)[C].中华医学会第九次全国消化系统疾病学术会议论文集.2009:38-45.
  • 6唐珂,卢丽霞,钟美佐,等.利妥昔单抗联合化疗治疗HBsAg阳性的非霍奇金淋巴瘤患者的安全性分析[J].医学临床研究,2015,(5):1026-1028.
  • 7Yang F, Zhu HL,He C, et al . Effect of Antiviral prophy-laxis strategy for chemotherapy-associated hepatitis b reacti-vation in non-hodgkirf s lymphoma patients with hepatitis bvirus infection: a retrospective cohort study [J]. Indian JHematol Blood Transfus,2014,30(2) :97-104.
  • 8Ifuku H, Kusumoto S,Tanaka Y,et al .Fatal reactivation ofhepatitis B virus infection in a patient with adult T-cell leuke-mia-lymphoma receiving the anti-CC chemokine receptor 4antibody mogamulizumab[J]. Hepatol Res ? 2015,45 ( 13):1363-1367.
  • 9秦建忠.氟达拉滨联合米托蒽醌与CHOP方案治疗恶性淋巴瘤的疗效及安全性[J].医学信息,2014,10(37):24-24.
  • 10高兰平,高国俊.中西医结合治疗淋巴瘤247例的临床分析[J].中国药业,2010,19(24):66-67. 被引量:5

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部